menu
    • menu
    [{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"DehydraTECH-Nicotine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pouch","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Lexaria Bioscience

    Menu

    Lexaria Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

                            Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.

                            Brand Name : DehydraTECH-tirzepatide

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 25, 2024

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexaria Study Shows DehydraTECH Outperforms Rybelsus® in Weight Control, Diabetes

                            Details : Oral DehydraTECH-technology processed liraglutide (GLP-1 agonist) is being investigated for obesity in comparison with Rybelsus (semaglutide).

                            Brand Name : DehydraTECH-liraglutide

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 20, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide,Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

                            Details : Oral DehydraTECH-technology processed semaglutide and liraglutide (GLP-1 agonist) is being investigated for obesity.

                            Brand Name : DehydraTECH-liraglutide

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 24, 2024

                            Lead Product(s) : Liraglutide,Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

                            Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.

                            Brand Name : DehydraTECH-liraglutide

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 22, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

                            Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.

                            Brand Name : DehydraTECH-tirzepatide

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 09, 2024

                            Lead Product(s) : Tirzepatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

                            Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.

                            Brand Name : DehydraTECH-Liraglutide

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 22, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

                            Details : DehydraTECH-CBD (cannabidiol) is a DehydraTECH-processed CB1 receptor negative allosteric modulator, which is being evaluated for the treatment of diabetes and weight loss.

                            Brand Name : DehydraTECH-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 05, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension

                            Details : DehydraTECH-CBD is protected by multiple patents in the USA and internationally and has received specific patent protection in both the EU and Australia for use in the treatment of heart disease.

                            Brand Name : DehydraTECH-CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed

                            Lexaria Bioscience

                            Canada arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DehydraTECH-Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

                            Details : DehydraTECH-nicotine is oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 05, 2021

                            Lead Product(s) : DehydraTECH-Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth